This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Law Firm Brower Piven Announces Investigation Of Investor Securities Fraud Against GenVec, Inc.

The law firm of Brower Piven, A Professional Corporation, is investigating potential securities fraud claims against GenVec, Inc. (“GenVec”) (NASDAQ: GNVC) regarding whether GenVec may have issued materially false or misleading information to investors before announcing on March 29, 2011 that it was discontinuing its Phase III clinical trial of TNFerade in patients with locally advanced pancreatic cancer.

Brower Piven has been retained to commence a securities class action lawsuit on behalf of GenVec investors to recover investment losses. If you purchased or acquired GenVec securities between March 12, 2009 and March 29, 2010 and have suffered a loss on your investment, or if you believe you have information relating to the subject matter of our investigation, you may email or call Brower Piven, who will, without obligation or cost to you, attempt to answer your questions. You may contact Brower Piven by email at hoffman@browerpiven.com, by calling 410/415-6616, or by writing to Brower Piven, A Professional Corporation, 1925 Old Valley Road, Stevenson, Maryland 21153. Attorneys at Brower Piven have combined experience litigating securities and other class action cases of over 60 years.

Copyright Business Wire 2010

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 17,704.16 -25.95 -0.15%
S&P 500 2,070.85 -5.93 -0.29%
NASDAQ 4,993.0150 -16.1990 -0.32%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs